Screening results in Hunan, China exceed expectations

NZX Announcement
2 September 2019
Screening results in Hunan, China exceed expectations
Highlights
•Screening results from 2,065 women across 7 hospitals in Hunan, China
exceed expectations
•TruScreen’s cervical cancer screening device demonstrates improved
sensitivity and specificity targeting pre-cancerous and cancerous cervical
cells
•Conducted by a peak gynaecology body in China, this evidence is a key
plank in TruScreen’s commercial platform
Real-time cervical cancer screening technology company TruScreen (NZX:TRU) is
pleased to announce that the clinical results of 2,065 women screened for cervical
cancer across seven hospitals in Hunan have exceeded expectations.
The China Obstetrics and Gynaecology Association (COGA) is conducting a project that
will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in
China. Hunan is the first province in China to complete their participation in the project.
The COGA evaluation compares the TruScreen technology to Liquid Based Cytology
(LBC), and HPV DNA testing (HPV) and will screen over 20,000 women in 100 top-tier
public hospitals across10 provinces in China .
COGA Hunan Province interim results showed TruScreen has a Sensitivity of
89.29% (LBC 67.87%, HPV 92.86%) and a Specificity of 87.17% (LBC 90.07%, HPV
84.26%).
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
LBCHPVTRUTRU and HPVLBC + HPV
Hanun Provice COGA Reuslts
SensitivitySpecificity

Sensitivity and specificity are measures of a test’s ability to correctly diagnose disease.
A high sensitivity results in fewer false negatives, and a high specificity results in fewer
false positives in the screening process.

Publication will occur when the full 20,000 patients have been screened. Interim results
from this Hunan clinical evaluation confirm the strong potential for the TruScreen device
to improve women’s health in China. The Chairperson of COGA Hunan, Professor Xue
Ming, presented the results at the Hunan Provincial COGA Annual Congress on
Saturday, 24 August 2019 in China.

Results Commentary

TruScreen Chief Executive Martin Dillon said: “We are delighted to be able to report such
strong results from the first completed province for the COGA evaluation.

Many hospitals and key opinion leaders have been waiting for such in country evidence
to finalise their purchasing and recommendation of our Truscreen devices.”
.


- ENDS -


For more information visit www.TruScreen.com or contact:

TruScreen
Martin Dillon
CEO
martindillon@truscreen.com

TruScreen
Guy Robertson
CFO
guyrobertson@truscreen.com
Investors
Investor Relations
Phone: +61 2 9237 2801
TruScreen@we-buchan.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device
which offers the latest technology in cervical
screening, providing real-time, accurate detection
of pre-cancerous and cancerous cervical cells to
help improve the health and well-being of women
around the world. TruScreen’s real-time cervical
cancer technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the surrounding
tissues. A sophisticated proprietary algorithm
framework is utilised to detect pre-cancerous change,
or cervical intraepithelial neoplasia (CIN), by optical
and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the
ongoing issues with Pap tests including failed samples, poor patient follow up, patient
discomfort and the need for supporting laboratory infrastructures. As such, TruScreen
target market is middle income countries where no large scale cervical cancer
screening programs and infrastructure are in place, such as; China, Mexico, Africa,
Russia and India. TruScreen’s cervical cancer screening device is EC certified for use
throughout Europe and CFDA approved for sale in China. The global market potential
for TruScreen is significant. At saturation, hundreds of millions of women could benefit
from this accurate and inexpensive cervical cancer screening model.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/